USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

US health regulator issues warning letter to Intas Pharmaceuticals CEO and MD Nimish Chudgar for manufacturing lapses and violation of CGMP regulations at the Matoda-Sanand facility in Ahmedabad. The USFDA found various manufacturing lapses and inadequate oversight in the company's Quality Assurance and production departments. Specifically, the investigation revealed manipulation of defect counts on visual inspection records to avoid rejection limits. The company also failed to thoroughly investigate discrepancies and establish written procedures for production controls and prevention of microbiological contamination.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/6jLQBWd
>

Comments

Popular posts from this blog

Koffee With Karan 7: Karan Johar refers to Shahid Kapoor as the ex-husband of Kareena Kapoor Khan and her expression is pure horror

BTS member V meets PSY and we are obsessed with this memorable reunion